# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted...
Brookline Capital analyst Kemp Dolliver downgrades POINT Biopharma Global (NASDAQ:PNT) from Buy to Hold and lowers the price...
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Ph...
Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SP...
Lantheus Holdings, Inc. (Lantheus) (NASDAQ:LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ:PNT) today announced statistic...
As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as ...